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PREVIOUS WORK HAS demonstrated the importance of the Protein Kinase C (PKC) signal transduction system in 
regulating the growth rate of malignant gliomas in vitro. Tamoxifen inhibits PKC in a minority of malignant gliomas 
within the micromolar concentration range in vitro, a property distinct from its estrogen receptor blockade effect. 
Tamoxifen was administered orally in very high dosages to 11 patients (9 males:2 females, age range 26-73, mean 45 
years) with malignant gliomas (anaplastic astrocytoma or glioblastoma multiforme) who had failed treatment with 
external beam radiation therapy (and additional chemotherapy in 2). The dosage administered was estimated to be 
that necessary to achieve tissue concentrations within the low micromolar range, shown necessary to inhibit PKC in 
these tumors in vitro, and is approximately 5 times that used for standard antiestrogen therapy. Tumor reduction on 
radiographic images (MR! and PET [18FdG uptake]) with clinical improvement occurred in 3 patients; halting of 
tumor progression clinically and radiographically occurred in an additional patient. Of the remaining seven patients, 
three patients had marked and rapid progression of their disease despite treatment (dead after 3, 4, and 6 months 
respectively). Complications of treatment included a deep venous thrombosis requiring anticoagulation in one patient, 
nausea in one patient, and "hot-flashes" in a third patient. Tumor biopsy and measurement of tamoxifen and its active 
metabolite within the tumor of one patient (non-responder) showed levels within the middle of the in vitro therar 
peutic range. Follow-up of alive patients ranges from 4-18 months (mean 10 months). These encouraging preliminary 
resul ts in a minority of these patients suggests some potential for this type of therapy. If PKC is the true target for any 
beneficial effect from tamoxifen therapy, this emphasizes the importance of clinical trials using other existing PKC i 
inhibitors with increased potency and specificity for PKC. (Neurosurgery 32:485-490 , 1993)
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P revious work has demonstrated that the proliferation rates 
of malignant gliomas are sensitive to modulators of Protein 
Kinase C (PKC) in vitro (1,3-7,17). Malignant gliomas 
express very high PKC activity when compared to non-trans- 
formed glial cells (2-3 orders of magnitude increase), both in 
human and rat systems (4-7). This high activity correlates strong­
ly with the proliferation rates of these tumors in vitro (4,6). 
Moreover, iden ti f ied gli oma m i togens such as Fibroblast Growth 
Factor (FGF) and Epidermal Growth Factor (EGF) enhance PKC 
activity, which correlates with the increase in 3H-thymidine
uptake produced by these growth factors. Altering enzyme 
activity by down-regulation or direct inhibition reduces the 
tumor growth rate significantly in vitro (1,3-217). Collectively 
these observations have supported an important role of the PKC 
system in regulating glioma growth and have led to the specu­
lation that PKC inhibitors maybe utilized as adjuncts in the ther­
apy of patients harboring malignant gliomas.
Tamoxifen, in a property distinct from estrogen receptor 
blockade, also inhibits PKC in the micromolar concentration 
range in these cells (1). An initial study administering low-dosage
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tamoxifen (40 mg/day) to patients with recurrent malignant 
gliomas, while failing to demonstrate statistically increased sur­
vival, has documented isolated cases with apparent response to 
the treatment (19). As the growth and PKC inhibitory response 
to tamoxifen is dose-dependent (1,16), the following study was 
undertaken to assess the clinical safety and possible efficacy of 
administering very high dosages of tamoxifen to patients with 
recurrent malignant glial tumors. We report a clinical and radi­
ographic (MRI and PET) response in a minority of patients 
administered high dosages of oral tamoxifen.
CLINICAL MATERIAL AND METHODS 
Patient Selection
Criteria for inclusion in this study included A) patients ages 
between 18 and 75 years; B) histologically verified malignant 
glioma (anaplastic astrocytoma or glioblastoma multiforme); C) 
clinically and radiographically documented progression or 
recurrence following radiation (and chemotherapy in some 
cases); and D) no intercurrent illness, such as other malignancy, 
history of previous malignancy, blood dyscrasias, gynecologi­
cal, ocular or gastrointestinal disease. From July 1991 to July 1992, 
14 patients were chosen for inclusion in this study, of which 11 
complied with treatment and were evaluable (Table 1; 9 males:2 
females, age range 26-72, mean 45 years). Three patients which 
were not evaluable included 2 cases of non-compliance and one 
case of rapid deterioration and death within one month in a very 
ill patient with recurrent glioblastoma multiforme.
Method of Treatment
All patients were screened for compliance and acceptance crite­
ria. All pathology was reviewed by one of the authors (DH). Baseline 
radiographic images (MRI) and blood work (Complete Blood 
Counts [CBC] and Serum Chemistry) were performed prior to ini­
tiation of therapy. Tamoxifen (ICI Pharmaceutical, Wilmington, 
Delaware) was first administered at standard antiestrogen doses 
(20 mg orally BID) to observe for any side effects. If tolerated, the 
dose was increased weekly to achieve target dose over a 1 month 
period (80 mg BID in females, 100 mg BID in males). CBC and Serum 
Chemistry panel were performed every 2 weeks while escalating 
the dose and every 2 months thereafter while on the drug.
Observation and Evaluation
Patients included for evaluation included those who tolera­
ted the drug at maximal dosages for a period of 2 months or 
longer, survived for at least one month following attainment of 
maximal therapy (to enable significant steady-state tissue levels 
of tamoxifen to be obtained), and were clinically and radi­
ographically evaluated during the treatment period.
All patients underwent initial and serial MRI imaging with 
and without gadolinium enhancement. Initial tumor volume 
was estimated by measuring the cross-sectional diameters at the 
level of the largest contrast-enhancing tumor extent. These mea­
sures were multiplied, and the product was multiplied by the 
extent of maximal enhancement on coronal studies. Estimation 
of the tumor volume excluded areas of cystic change or edema. 
Subsequent comparison studies chose comparable MRI slices 
with tumor measurement by the same technique.
Serial PET scans were performed on 7 patients during treat­
ment. Each subject received 10 mCi of 18F-fluorodeoxyglucose, | 
and images of relative glucose metabolism were obtained 30-40 I 
minutes following tracer injection. Image acquisition was per­
formed over a 30 minute period using a Siemens 953-A tomo­
graph. Plane thickness was 3.4 mm and reconstructed in-plane 
image resolution was 7 mm full width half maximum. All images 
were normalized to an equivalent index for normal cortex, to ; 
enable comparison of tumor site. Forcomparisonstudies, images 
were chosen to incorporate the region of maximal glucose metab­
olism, and were visually inspected for regional changes. :
Treatment response (R) was defined as a greater than 50% 
decrease in volume of the enhancing lesion volume on MRI and 
a decrease in metabolic activity (18FdG uptake) on PET scans 
with clinical neurological improvement (including Karnofsky 
scores). Stabilization or no change (NC) was defined as <50% 
reduction in tumor volume radiographically and no clinical pro­
gression. Progressive disease (PD) included all other patients 
(worsening clinically or radiographically). Corticosteroid 
dosages in all patients were either maintained or decreased on 
comparison radiographic studies.
In one patient (A.J.), tumor tissue levels of tamoxifen and its 
active metabolite N-desmethyltamoxifen were measured in a 
snap frozen surgical tissue specimen by Normal-Phase High 
Pressure Liquid Chromatography (HPLC).
RESULTS 
Side Effects
Three patients exhibited side effects during the course of their 
treatment. One patient developed nausea following dose esca­
lation of tamoxifen. The persistence of the nausea prompted tem­
porary withdrawal of therapy, with no resolution of the 
symptom, The drug was restarted and the symptom slowly 
resolved. Another minor complication was "hot-flashes" expe­
rienced by a young female just after initiation of therapy. One 
major complication encountered was a deep venous thrombo­
sis in an elderly male on maximal therapy for a period of 12 
weeks, which was managed by anticoagulation following dis­
continuation of therapy.
Response Rate
Table 1 summarizes the response and follow-up of the 11 evalu­
able patients on high dose tamoxifen therapy. Response (R) was 
noted in 3 patients, with improvement clinically and radiograph­
ically (Figures 2 and 3). The 2 responding patients shown in the 
illustrative cases both harbored glioblastoma multiforme, with 
one patient failing 2 previous clinical protocols of a) CCNU, 
Vincristine and Procarbazine, and b) Carboplatin chemotherapy. 
These 3 responders have all survived longer than 12 months, with 
clinical improvement. Another patient has demonstrated no 
change (NC) in clinical status and radiographic images over the 
follow-up period (6 months). Three patients had marked and rapid 
progression of disease while on therapy which resulted in death 
at 3,4 and 6 months following initiation of therapy (Figure 1). The 
remainder of the non-responding cohort has demonstrated either 
clinical or radiographic deterioration over the follow-up period.
Measurement of tamoxifen and its active metabolite
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FIGURE 1. This 68-year-old male presented with a v a g u e ly  enhancing right parietal mass (A) which revealed anaplastic astrocy­
toma by stereotactic biopsy. Recurrence of tumor o c c u r r e d  shortly following radiation therapy, and he was placed on high dose 
tamoxifen therapy. The lesion quickly progressed c l in ic a lly  over the ensuing weeks, as documented by MRI (B) and PET scan 
(FdG uptake, C). Following the development of a d e e p  venous thrombosis (DVT) the patient was discontinued from therapy and 
he succumbed to the tumor 16 weeks following the s t a r t  of therapy. Autopsy revealed glioblastoma multiforme.
FIGURE 2. A 49-year-old male, with recurrent b ifro n ta l butterfly glioblastoma 7 months following partial surgical resection and 
external beam radiotherapy. The patient had been in it ia lly  started on tamoxifen 40 mg/day, with slight radiographic progression 
of tumor despite therapy (comparison of the N o v e m b e r  (A) and December (B) MRI study performed 6 weeks later demonstrates 
increased enhancement and further extension th r o u g h  the corpus callosum). Dosage was increased to 100 mg BID, which was 
followed by a marked decrease in size of enhancing tu m o r on MRI 2 months following (C). Follow-up studies 9 months later 
indicate no change in the scans (D). The patient w a s  n ever placed on corticosteroid therapy during the course of treatment,
The small residual enhancing lesion on the MRI c o n t in u e s  to show a decrease in metabolic activity on later serial PET images (E). 
The patient is neurologicaily intact.
N-desmethyltamoxifen in the tumor of one n on -resp on d in g  
patient (A.J.) who underwent a temporal lo b e c to m y  showed 
levels of 2.6 and 11 micromolar respectively.
Median survival for the entire cohort was 6 m o n t h s ,  with a 
mean length of follow-up of 8.4 months (36 weeks). Iv lea n  length 
of follow-up of alive patients is 10 months (43 w e e k s ) .
Radiographic Observations
Radiographic response is shown in Table 1. The p a tien ts  who 
had regression of enhancement on MRI images a l s o  demon­
strated a decrease in metabolic activity on PET s c a n s  (Figures 2 
and 3). The patient who has remained clinically u n c h a n g e d  has 
had a halting of progression on MRI scan. All o t h e r  patients 
demonstrated progressive disease either on PET o r  IVIRI studies.
DISCUSSION
Intracellular transmission of growth factor s i g n a l s  is pre­
sumed to be mediated by a network of seq u en tia lly  activated 
protein kinases. Protein Kinase C (PKC) has b een  im plicated in 
the transduction of cellular responses to various a g o n is t s  includ­
ing hormones, neurotransmitters, and some growth factors in 
selected cell types (11-13). In this regard, recent reports have iden­
tified some mitogenic growth factorsignals whichmaybe trans­
duced through PKC in malignant gliomas and non-transformed 
glial cells (6,20). The observations of high PKC activity in frozen 
surgical malignant glioma tissue (6), together with the demon­
strated strong coupling of PKC activity and proliferation rate in 
vitro (4,6), suggest that this enzyme activity may function as a 
chemotherapeutic target in vivo.
Tamoxifen has previously been shown to inhibit PKC another 
cell types (14,15) and to decrease the proliferation rates of estab­
lished glioma cell lines in vitro (1,16). It also inhibits approxi­
mately 25-30% of low-passage glioma specimens in vitro (1). The 
results from the present study indicate that high-dose oral 
tamoxifen appears to be well tolerated in most patients, and may 
inhibit tumor growth in a minority of patients with recurrent 
malignant gliomas. This response in a patient to high-dose 
tamoxifen has also recently been noted by another group (2, 
Yong, VW. and Baltuch, G., McGill University, personal com­
munication). The concentration of tamoxifen necessary for PKC 
inhibition in these cells lies within die micromolar range in vitro
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FIGURE 3. This 38-year-old male had deteriorated clinically and radiographically through 2 experimental chemotherapy protoco 
with nitrosureas and carboplatin for treatment of glioblastoma over a period of 9 months since the tumor was first diagnosed. 
Clinically he had developed a rapidly progressing expressive aphasia with right hemiparesis. MRI scan revealed the cystic left frontc 
temporal mass prior to tamoxifen therapy (A). Following surgical drainage of his temporal cysts and resection of glioblastoma 
from the anterior temporal tip, the patient was started on high dose tamoxifen therapy. Subsequent postoperative MRI studies pe 
formed at 6 weeks (March; B) and 11 months (December; C) following initiation of therapy indicate regression of the enhancing 
tumor in the region of the basal ganglia and fronto-temporal region distant from the surgery; the patient's clinical status has 
improved markedly paralleling the radiographic changes. Serial PET studies also indicate a decrease in glucose metabolism withii 
these regions (D). He is presently 12 months duration on tamoxifen with continued clinical improvement, with total resolution of 
hemiparesis and marked improvement in expressive aphasia. He is currently on no corticosteroid therapy.
(1,16); measurement of the drug and its active metabolite in the 
tumor of one of the patients in our own study indicate that siz­
able dosages must be administered to achieve this, far greater 
than those used clinically for blockage of the estrogen receptor. 
This dose-dependency was illustrated by one patient (H.G.; 
Figure 2), who was progressing on low-dose therapy yet 
responded to high-dose tamoxifen. Lack of toxicity with this 
type of therapy makes itparticularly appealing for use in patients 
with extensive malignant disease, despite the fact that extended 
therapy is necessary due to its "tumoristatic" nature (ie., it slows 
or halts tumor cell proliferation rather than killing the cell). 
Moreover, recent laboratory work has demonstrated it may also
potentiate the effect of radiation therapy in malignant glioma cell 
possibly also mediated by a PKC-dependent mechanism (21).
Of interest is the clinical and radiographic response of on 
patient (J.B.; Figure 3) in the present study who had previousl 
failed 2 chemotherapeutic drug protocols, indicating that th: 
type of treatment may prove suitable as salvage therapy follow 
ing standard chemotherapy in some patients.
Prediction of the tumors that may respond to this type of thei 
apy is unknown at present. However, a potentially importar 
observation is that the percentage of patients that appear t 
respond to high dose tamoxifen therapy is similar to the nurr 
ber of low-passage glioma lines that are sensitive in vitro (1), suj
TABLE 1. Clinical Data















H.C. M, 49 Glioblastoma Bifrontal 90 surg, rad 200 R + 100 18
A.J. F, 36 Glioblastoma L-Temporal 60 surg, rad 160 PD - 6t
D.T. M, 37 A. Astrocytoma R-Fronto-Parietal 60 rad 200 R + 70 15
J.B. M, 38 Glioblastoma L-Fronto-Temporal 70 surg, rad, chemo 200 R + 80 12
J.Z. M, 68 A. Astrocytoma R-Parietal 70 rad 200 PD _ 4 t
A.S. M, 42 A. Astrocytoma R-Frontal 60 rad 200 PD - 10+
E.R F, 73 Glioblastoma R-Frontal 50 surg,rad 160 NC + 50 6
M.V. M, 35 Glioblastoma Cerebellar 80 surg, rad 200 PD - 70 6
D.M. M, 26 A. Astrocytoma R-Parietal 90 rad 200 PD + 90 8
L.D. M, 56 Glioblastoma L-Parietal 40 surg, rad 200 PD - 3 t
R.S. M, 36 A. Astrocytoma L-Parietal 60 surg, rad, BCNU 200 PD - 50 4
aA.= Anaplastic
bsurg = craniotomy with tumor reduction; all others underwent stereotactic biopsy only 
crad = external beam radiation therapy
dchem o = chemotherapy (1: CCNU, Vincristine, Procarbazine, 2: Carboplatin) 
eR = response, NC = no change, PD = progressive disease 
f+ = improvement, + = equivocal, -  = negative 
s + -  death
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gesting that in vitro-sensitivity testing may be feasible. The pres­
ence of the amplified KGF-receptor (ECFR) and its gene noted 
in a significant proportion of glioblastoma specimens (8,9), and 
the observation of the increased response of patients harboring 
glioblastomas as compared to anaplastic astrocytomas in the 
present study suggest the interesting hypothesis that this ampli­
fied receptor may increase I’KC activity and thus tamoxifen sen­
sitivity in these patients (6).
The definition of the true efficacy of high-dose tamoxifen in 
patients harboring malignant gliomas is not possible from this 
limited pilot study and will require larger Phase II trials. 
However, it PKC' is the target for any beneficial effect in these 
patients, then future clinical work should focus upon adminis­
tration of more specific and/or potent PKC inhibitors which 
already exist (4,(1,111). For example, whereas tamoxifen inhibits 
only a minority of low-passage glioma lines in vitro, the potent 
(though only relatively specific) PKC inhibitor Staurosporine 
inhibits all glioma tumors tested within the lownanomolar range 
(1,4,6), suggesting agents such as this may prove to be more favor­
able for the treatment of these lesions, [ntratumoral adminis­
tration of this agent or a derivative has been shown to inhibit 
tumor growth in an in vivo glioma model (unpublished data) 
and systemic therapy to inhibit the growth and invasion of other 
in vivo tumors (10,18).
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COMMENTS
There has been considerable interest in finding new bio­
chemical pathways which are involved in controlling the growth 
of malignant gliomas. The Protein Kinase C pathway has been 
of particular interest. This is in part because of the fact that there 
are a variety of potential therapeutic agents which cart modu­
late this pathway. Of these agents, tamoxifen is perhaps the most 
clinically relevant at the present time.
In this paper, the results of a clinical trial of tamoxifen in a 
small series of glioma patients appears to be encouraging and 
form the basis for making further studies of the potential value
of this concept. _
It is of particular interest that an agent such as tamoxifen 
would play a therapeutic role inasmuch as it does not have 
many of the toxic side effects of standard chemotherapy agents 
and is therefore a potentially valuable approach as an alternate 
to alkylating agents and even as an adjunct to cytotoxic
chemotherapy- P» l Komblith
Pittsburgh, Pennsylvania
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The authors describe the clinical effects of high-dose tamox­
ifen on 11 patients with recurrent glioblastomas. A positive 
response was obtained in a minority of the patients treated with 
high doses (3 of 11 cases). This kind of therapy is new in the field 
of neurooncology and this preliminary report is thus very impor­
tant, as was the previous one on the same topic with lower doses 
(reference 19). Although this clinical trial is based on outstand­
ing laboratory work on protein kinase C (PKC) activity in 
glioblastoma cells done by the first author, the mechanisms of 
action of tamoxifen deserve some comments.
1.Tamoxifenis known to haveseveralbiological activities includ­
ing estrogen inhibiting action (antagonism of estrogen-receptor 
binding) (4); protein kinase C inhibition (by membrane-substrate 
protein interaction) (5); and inhibition of calmodulin-independent 
Ca2+ transport system (6). As mentioned by the authors, several 
studies suggest that tamoxifen inhibits the PKC activity of gliobl as- 
toma cells, however there is no direct proof that this was actually 
the mechanism of action in the patients.
2. Protein kinase C is a major pathway of signal transduction 
for many peptide growth factors and hormones, and is therefore 
necessary for the survival and growth of various normal cells as 
well as the neoplastic cells. Administration of a potent inhibitor 
of PKC might cause severe toxicity on hematopoiesis and even 
on the brain function (7), and should be done with caution.
3. Receptors for epidermal growth factor (2) and fibroblast 
growth factor (3,8) have tyrosine kinase domains and their sig­
nal transductions do not enhance PKC activity directly. EGFR 
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This article by Couldwell et al. is interesting and provocative. 
However, the study is very small, with only 11 patients dispersed 
between two malignant histologies, anaplastic gliomas and 
glioblastomas multiforme, in addition, the median follow-up for 
the study is only 8.4 months. Under the circumstances, one can­
not be certain of the true benefit of tamoxifen.
This study, while showing some activity, has insufficient data 
upon which to judge true efficacy of this therapy. There are only 
hints of activity at this time, which are provocative and may in 
fact be harbingers of an important study.
I believe that the authors have to conduct a proper study and 
increase the number of patients to an appropriate number for 
phase II studies of this kind. Normally, most statisticians, once 
activity has been dem onstrated, w ill require som ew here 
between 17 and 20 patients for each histology to get good con­
fidence intervals on the relative activity of the study. There needs 
to be a more careful analysis of anaplastic astrocytoma vs. 




With recent advances in the understanding of basic tumor 
biology, it is now apparent that tumors originate and progress 
because of abnormal regulation of normal cellular biochemi­
cal and physiological processes. A common feature of abnor­
mal cell biology in cancer is that of an alteration in one or more 
of the pathways by which external signals, such as growth fac­
tors, are conveyed to the intracellular constituents, the signal 
transduction pathways. This recognition provides multiple 
new targets for anticancer treatment and, thus, perm its the 
potential of developing therapies that do not simply depend on 
direct interaction of the therapeutic agent with production of 
DNA by the tumor, as is the case with most forms of standard 
chemotherapy.
Protein kinase C, an enzyme activated by receptor-mediated 
hydrolysis of inositol phospholipids, relays information in the 
form of a variety of extracellular signals across the cell membrane 
to regulate many Ca2+ -  dependent processes. Protein kinase C 
is activated, as assayed by the phosphorylation of its endogenous 
stibstrates, by tumor promoting agents, such as thephorbol esters, 
and has enhanced activity in malignant gliomas. Couldwell et al. 
demonstrate clear evidence of antitumor activity of tamoxifen, 
an inhibitor of protein kinase C, in patients with recurrent malig­
nant gliomas, with minimal associated toxicity. Not only is this 
observation important because of the potential benefit that such 
treatment may have alone, but also for the potential of using this, 
or other, more potent, inhibitors of protein kinase C, combined 
with conventional therapies, or combined with other new agents 
that selectively target additional points of vulnerability that have 
been exposed by basic research in tumor cell biology, for more 
effective tumor control and less toxicity than the limited choices 
now available.
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